NCT03760276View on ClinicalTrials.gov

A Study to Evaluate the Appropriateness of the Voriconazole Dosing Regimen

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

August 20, 2018

Primary Completion Date

October 28, 2018

Study Completion Date

October 28, 2018

Conditions
Fungal Infection
Interventions
DRUG

Voriconazole Oral Product (Vfend®)

To be determined mg of Voriconazole (Vfend®, anti-fungal agent)

Trial Locations (1)

03080

Seoul National University Hospital Clinical Trial Center, Seoul

All Listed Sponsors
lead

Seoul National University Hospital

OTHER

NCT03760276 - A Study to Evaluate the Appropriateness of the Voriconazole Dosing Regimen | Biotech Hunter | Biotech Hunter